Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Company Overview

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

Key Stats

• Today's Range: $2.11 to $2.29
• 50-Day Range: $2.15 to $2.60
• 52-Week Range: $2.00 to $3.67
• Volume: 191,327 shs
• Average Volume: 353,080 shs
• Market Capitalization: $86.67 million
• P/E Ratio: 19.55
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Oramed Pharmaceuticals Stock Analysis - MarketRank™

Oramed Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat, and ranked 734th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Oramed Pharmaceuticals.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.03) to ($0.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oramed Pharmaceuticals is 19.55, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.57.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oramed Pharmaceuticals is 19.55, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.46.

Price to Book Value per Share Ratio

Oramed Pharmaceuticals has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.57% of the outstanding shares of Oramed Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oramed Pharmaceuticals has recently decreased by 6.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oramed Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Oramed Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.57% of the outstanding shares of Oramed Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oramed Pharmaceuticals has recently decreased by 6.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Oramed Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

7 people have searched for ORMP on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Oramed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.70% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

ORMP Stock Analysis - Frequently Asked Questions

How have ORMP shares performed this year?

Oramed Pharmaceuticals' stock was trading at $2.42 at the beginning of 2025. Since then, ORMP stock has decreased by 11.2% and is now trading at $2.15.
View the best growth stocks for 2025 here.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its earnings results on Monday, January, 10th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.06. The biotechnology company earned $0.67 million during the quarter, compared to analysts' expectations of $0.70 million.

Who are Oramed Pharmaceuticals' major shareholders?

Top institutional shareholders of Oramed Pharmaceuticals include BML Capital Management LLC (6.56%), Boothbay Fund Management LLC (2.10%), Two Sigma Advisers LP (0.60%) and Peapod Lane Capital LLC (0.56%). Insiders that own company stock include Michael Rabinowitz, Nadav Kidron and Kevin Rakin.
View institutional ownership trends.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 1/10/2022
• Today: 2/21/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORMP
• CUSIP: N/A
• CIK: 1176309
• Web: www.oramed.com
• Phone: (844) 967-2633
• Fax: 972-2566-0004
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.11
• Trailing P/E Ratio: 19.55
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $5.53 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -7.27%
• Return on Assets: -6.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 27.08
• Quick Ratio: 27.08

Sales & Book Value

• Annual Sales: $1.34 million
• Price / Sales: 64.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 0.53

Miscellaneous

• Outstanding Shares: 40,310,000
• Free Float: 34,789,000
• Market Cap: $86.67 million
• Optionable: Optionable
• Beta: 1.66